Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5660
Revised: November 15, 2013
Accepted: January 3, 2014
Published online: May 21, 2014
Processing time: 226 Days and 20.1 Hours
Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer (GC) development, which is one of the most challenging malignant diseases worldwide with limited treatments. In the multistep pathogenesis of GC, H. pylori infection slowly induces chronic active gastritis, which progresses through the premalignant stages of atrophic gastritis, intestinal metaplasia, and dysplasia, and then finally to GC. Although eradication of H. pylori is a reasonable approach for the prevention of GC, there have been some contradictory reports, with only some long-term follow-up data showing efficacy of this approach. The inconsistencies are likely due to the insufficient number of participants, relatively short follow-up periods, poor quality of study designs, and the degree and extent of preneoplastic changes at the time of H. pylori eradication. This review analyzes recent high-quality studies to resolve the discrepancies regarding the eradication of H. pylori for GC prevention. The relationship between H. pylori eradication and GC/precancerous lesions/metachronous GC is examined, and the cost-effectiveness of this strategy in the prevention of GC is assessed. Although it is assumed that eradication of H. pylori has the potential to prevent GC, the feasibility and appropriate timing of this strategy for cancer prevention remain to be determined. As a result, additional well-designed trials with longer follow-up periods are needed to clarify this issue.
Core tip: The treatment of gastric cancer (GC) is challenging. Elimination of a major risk factor, Helicobacter pylori (H. pylori) infection, represents an important approach for the prevention of GC. However, the feasibility and appropriate timing of this strategy remain to be determined. This review highlights the most recent literature and presents a comprehensive evaluation of what is currently known about H. pylori infections and GC.
-
Citation: Lu B, Li M.
Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014; 20(19): 5660-5665 - URL: https://www.wjgnet.com/1007-9327/full/v20/i19/5660.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i19.5660
Gastric cancer (GC) represents one of the most challenging malignant diseases worldwide and is the second leading cause of death with the highest incidence rates observed in Eastern Asia, Japan, Eastern Europe, and the Andean regions of South America[1]. GC develops from the progression of chronic gastritis to gastric atrophy, intestinal metaplasia, dysplasia, and finally invasive carcinoma[2]. Although the development of GC involves a multifactorial pathway, the pathogenesis is believed to begin from a single infectious agent[3,4], Helicobacter pylori (H. pylori), which is classified as a Group 1 carcinogen by the World Health Organization (WHO) and International Agency for Research on Cancer (IARC)[5]. H. pylori is a leading worldwide infectious agent, accounting for as many as 650000 new cases of non-cardiac GC annually[6], and epidemiological data support a strong causal relationship between H. pylori infection and GC[7-11], as well as some animal studies[12-14]. Different countries have different consensus reports about H. pylori eradication treatment[15-20]. Among these guidelines, the most consistent recommendation with a high level of evidence is endoscopic resection of early GC[21]. H. pylori eradication is recommended to improve gastric atrophy[22]. Although it may seem intuitive that removing the organism would eliminate the risk of GC, only a small proportion of infected individuals develop GC[23]. Furthermore, massive eradication therapy may lead to activation of antibiotic-resistant strains of H. pylori in the general population, as well as an over-consumption of medical resources. Therefore, this review integrates information available from recent studies in order to evaluate the benefit of H. pylori eradication for GC prevention.
The first well-designed trial to investigate eradication of H. pylori for the prevention of GC was performed in 1991 by Correa et al[24] and involved Colombian individuals at high risk for GC. Although the cancer incidence was similar in both treated and untreated groups after a 6-year follow-up, this trial showed significant increases in the regression rates of cancer precursor lesions. In 2004, Wong et al[25] assigned 1630 patients from the Fujian province in China with H. pylori infections to an eradication or a non-eradication group. During the 7.5-year follow-up period, GC was similar in both groups, occurring in 11 out of 813 patients from the non-eradication group and seven of 817 patients from the eradication group. However, the incidence of GC in a subgroup without precancerous lesions receiving H. pylori eradication therapy was significantly lower, compared with the non-eradication group; several other trials reported similar results[26-27].
A meta-analysis by Fuccio et al[28] examined six randomized trials assessing GC and the progression of preneoplastic lesions during 4-10 years follow-up. Their results indicated that 27 of 3388 patients (1.1%) in the H. pylori antibiotic treatment group developed GC, compared to 56 of 3307 (1.7%) not undergoing treatment; the overall relative risk was 0.65. However, this meta-analysis comprised mainly studies performed in Asia, and only two of the studies were of a double-blind design. With a cohort study of 80225 patients, Wu et al[29] found that the earlier H. pylori is eradicated after peptic ulcer disease, the smaller the risk of GC, with no risk for patients receiving early H. pylori eradication as compared to the general population. A later interventional trial in Shandong, China showed that 2 wk antibiotic treatment for H. pylori in 3365 patients significantly reduced GC incidence by 39%, during a total follow-up of 14.7 years[30].
Altogether, most of these studies focused on people with gastric precancerous lesions, such as gastric atrophy and intestinal metaplasia (IM), because of the low incidence of GC. However, GC has a long pre-malignancy phase that may mask the ultimate effects of H. pylori eradication. Therefore, some results of previous studies are inconclusive, partly due to the insufficient number of participants and the relatively short follow-up[31,32]. Nonetheless, the above studies provide clinical evidence suggesting that successful eradication of this organism is related to a reduction in the risk of GC, although it does not prevent GC completely.
H. pylori infection can cause chronic gastritis. This chronic condition can lead to gastric mucosal atrophy and IM[2], which are considered to be precancerous lesions of GC[2,33-35]. Therefore, improvement or elimination of atrophy and IM with H. pylori eradication could potentially inhibit gastric carcinogenesis. Although the effect of H. pylori eradication on the incidence of precursor lesions is unknown, many studies have identified alterations in gastric atrophy and IM after H. pylori eradication. These reports had contradictory results, with several studies showing improvements in atrophy and IM[36-38], and others showing no improvement in the gastric mucosa after eradication[39-41]. There is also evidence that H. pylori eradication can lead to regression of atrophy in other conditions[42]. However, these studies were limited to data from short-term follow-up, small sample sizes, and few points of observation in their design, which may have contributed to the contradictory results.
A study by our team followed chronic atrophic gastritis patients with H. pylori infections, with only 92 of 179 patients receiving H. pylori eradication. Although the grade of IM increased in the untreated H. pylori-infected group after 3 years, the grade of atrophy significantly decreased in the eradication group, suggesting that H. pylori eradication may improve gastric atrophy and prevent the progression of IM[43]. However, a more recent meta-analysis that systematically reviewed the long-term effects of H. pylori eradication on gastric histology showed that H. pylori eradication can improve atrophy but not IM[22]. Recently, a trial from Matsu Island demonstrated that population-based eradication of H. pylori infection was associated with a significant reduction in gastric atrophy within the relatively short study period[44]. Evidence for the prevention of GC by reducing the occurrence of precancerous lesions was presented by Kodama et al[45], who evaluated the gastric mucosa at five points in the stomach according to the updated Sydney system and showed that atrophy at all sites and IM in the lesser curvature of the corpus were gradually and significantly decreased 10 years after the H. pylori eradication.
It is noteworthy to mention that GC can still develop even after successful eradication therapy. One famous case report describes two patients who were included in one of the first study cohorts that received eradication therapy for peptic ulcer disease, but nevertheless developed GC during long-term follow-up (one at 4 years and the other at 14 years after the H. pylori eradication)[46]. Both patients had suffered from IM when the gastric ulcer disease was first discovered. Furthermore, malignant lesions that develop after eradication therapy have a similar characteristic appearance to and therefore may have a common carcinogenesis with cancers that occur in the presence of H. pylori infection, although biological features may be changed by the eradication therapy[47,48]. These results suggest that H. pylori eradication does not result in the regression of all precancerous lesions, which may depend on the degree and extent of preneoplastic changes at the time of eradication. Moreover, decreased H. pylori colonization density may occur in these lesions even without active intervention, with further progression of premalignant lesions less dependent on H. pylori infection. Therefore, the key question is whether and when precancerous lesions can be reversed with H. pylori eradication. Ongoing clinical studies are focusing on a “point of no return”, defined as a situation when certain alterations are no longer reversible by H. pylori eradication and GC progression continues.
Following endoscopic resection of early gastric cancer (EGC), secondary cancers are often found at sites other than the resection site during follow-up, with the rates ranging from 3% to 4% per year[21,49,50], rendering them more likely to be detected in trials compared to the low incidence of GC. Japanese guidelines recommend treatment for H. pylori infection in patients following resection of EGC[51,52]. In 1997, Uemura et al[53] assigned patients undergoing endoscopic resection for GC to an H. pylori eradication group or a non-eradication group. Secondary GC was detected in 10 of 67 patients from the non-eradication group (15%) vs none of the 65 patients from the eradication group during about 5 years follow-up, suggesting that H. pylori eradication inhibits the development of new carcinomas. Although this was a pioneer study, it was not a randomized controlled trial. Fukase et al[21] reported the first multicenter, open-label, randomized study on the incidence of developing metachronous GC following endoscopic resection of EGC. In this study, 544 patients from 51 Japanese institutions were randomly assigned to an H. pylori eradication group or a non-eradication group and were followed up over 3 years with annual endoscopy to detect any recurrence of GC. This trial demonstrated a 65% risk reduction for the development of metachronous GC with H. pylori eradication. Long-term results of this trail were encouraging[54]. However, two recently published retrospective studies failed to validate these findings, suggesting that H. pylori eradication does not significantly prevent metachronous GC[49,55]. Nonetheless, a large retrospective study showed that recurrence rates and recurrence-free survival differed significantly between the non-eradication and eradication groups[56]. As for subtotal gastrectomy, Cho et al[57] reported that there was no difference in the development of metachronous GC according to the treatment allocation or final H. pylori status, which should be evaluated in further studies because bile reflux was reported to act as a carcinogen for later GC development[58,59].
Unlike gastric resection, endoscopic resection preserves the abnormal mucosa and gastric environment, which may promote the occurrence of secondary cancer in cases with atrophic gastritis or IM caused by H. pylori infection. Some available evidence suggests that H. pylori eradication reduces the incidence of metachronous GC in patients with a history of gastric adenoma. However, opposing results also indicate that the progression of atrophic gastritis and IM to GC can indeed occur following H. pylori eradication. Thus, there must be additional factors, such as genetic and epigenetic alterations, that lead to the progression of these preneoplastic lesions.
Several studies have indicated that the screening and eradication of H. pylori is a cost-effective strategy for the prevention of GC in middle-aged adults, even if the treatment prevents only 20%-30% of H. pylori-associated cancers[60,61]. Parsonnet et al[62] carried out a cost-benefit analysis of H. pylori screening and eradication in individuals aged 50 years. With an assumption that H. pylori treatment prevents 30% of GC, cost-effectiveness was estimated to be $25000 per year of life saved, and < $50000 per year of life saved for high-risk individuals, such as Japanese-Americans, even at a 5% treatment efficacy. The authors concluded that the screening and eradication of H. pylori was therefore a cost-effective strategy for preventing GC, especially in high-risk populations. Another study reported that the screening and eradication of H. pylori in young adults has the potential to prevent one in every 4-6 cases of GC in China, and would be considered cost-effective using the GDP per capita threshold[63]. A study from Shin et al[64] evaluated the long-term cost-effectiveness of H. pylori eradication in a selective population with a high risk of developing GC with estimated model variables based on an extensive review of published reports. Their analysis suggests little difference in H. pylori eradication costs ($29780 vs $30594 for no eradication) or in saving of lives (mean life expectancy from eradication: 13.60 years vs 13.55 years for no eradication). Although screening and eradication appear to be a cost-effective way to prevent GC, shortcomings in the therapeutic armamentarium along with a concern for antibiotic resistance should prevent recommendation of this global screen-and-treat strategy.
A prophylactic H. pylori vaccine could be an attractive alternative strategy for the control of H. pylori infections. A 2009 study evaluated the potential socioeconomic benefit of a putative H. pylori vaccine in three different simulated scenarios: no intervention, vaccination of infants, and vaccination of school-age children[65]. Results of their direct transmission model indicated that the use of a prophylactic H. pylori vaccine was cost-effective in the United States, with vaccination in infancy providing the greatest benefit over at least 40 years, at a cost per quality-adjusted life year of $17684.
H. pylori infection induces progressive inflammatory changes in the gastric mucosa that may lead to GC. As the treatment of GC represents a significant medical burden and poor outlook[66], H. pylori screening and eradication is likely to be one of the most promising and cost-effective approaches in GC prevention. However, the collective results of previous studies have failed to identify a significant reduction in GC; possibly due to the variable prevalence of H. pylori infection between countries and the long course of GC. Nevertheless, younger individuals with no precancerous lesions should consider H. pylori eradication for GC prevention, although high-risk groups should combine this therapy with endoscopic surveillance or treatment. Following endoscopic resection of EGC, H. pylori eradication should be used to prevent the development of metachronous gastric carcinoma, although study of the benefits in a wider population is needed.
H. pylori, which is often acquired during childhood and associated with low socioeconomic status, is recognized as a necessary but insufficient cause of GC, because the pathogenesis of gastric carcinogenesis is multifactorial. Although the mass eradication of H. pylori is potentially feasible, doubts remain about the advisability of such a policy. Differences in the socioeconomic composition of countries and the undesirable side effects of antibiotic use as well as increased incidence of other diseases necessitate further investigation into mass eradication of H. pylori as a preventative strategy[67-70]. In addition, the feasibility and appropriate timing of this strategy for cancer prevention remains to be determined. Further systematic data collection comprising large randomized controlled trials designed in multiple geographical areas and with extended follow-up periods is needed to elucidate the role of H. pylori eradication for GC prevention in patients with or without precancerous lesions.
P- Reviewers: Kouraklis G, Nardone G, Schneider R S- Editor: Qi Y L- Editor: Kerr C E- Editor: Liu XM
1. | Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11128] [Cited by in F6Publishing: 11691] [Article Influence: 899.3] [Reference Citation Analysis (4)] |
2. | Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-6740. [PubMed] [Cited in This Article: ] |
3. | Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132-1136. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1302] [Cited by in F6Publishing: 1209] [Article Influence: 36.6] [Reference Citation Analysis (0)] |
4. | Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2805] [Cited by in F6Publishing: 2681] [Article Influence: 81.2] [Reference Citation Analysis (0)] |
5. | Schistosomes , liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. [PubMed] [Cited in This Article: ] |
6. | de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607-615. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1583] [Cited by in F6Publishing: 1710] [Article Influence: 142.5] [Reference Citation Analysis (0)] |
7. | Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373-2379. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 268] [Cited by in F6Publishing: 264] [Article Influence: 10.6] [Reference Citation Analysis (0)] |
8. | Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, Blaser M, Wu Y, Zou X, Dong Z, Taylor P. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001;93:226-233. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 79] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
9. | El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, Williams C, Fullarton G, McColl KE. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000;118:22-30. [PubMed] [Cited in This Article: ] |
10. | Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3126] [Cited by in F6Publishing: 3056] [Article Influence: 132.9] [Reference Citation Analysis (0)] |
11. | Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347-353. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 704] [Cited by in F6Publishing: 719] [Article Influence: 31.3] [Reference Citation Analysis (0)] |
12. | Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T, Shimizu N, Tatematsu M. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res. 1998;58:2067-2069. [PubMed] [Cited in This Article: ] |
13. | Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998;115:642-648. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 689] [Cited by in F6Publishing: 657] [Article Influence: 25.3] [Reference Citation Analysis (0)] |
14. | Brenner H, Bode G, Boeing H. Helicobacter pylori infection among offspring of patients with stomach cancer. Gastroenterology. 2000;118:31-35. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 88] [Cited by in F6Publishing: 90] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
15. | Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1-20. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 282] [Cited by in F6Publishing: 286] [Article Influence: 20.4] [Reference Citation Analysis (0)] |
16. | Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587-1600. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 384] [Cited by in F6Publishing: 405] [Article Influence: 27.0] [Reference Citation Analysis (1)] |
17. | Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 819] [Cited by in F6Publishing: 804] [Article Influence: 47.3] [Reference Citation Analysis (2)] |
18. | Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646-664. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1541] [Cited by in F6Publishing: 1514] [Article Influence: 126.2] [Reference Citation Analysis (4)] |
19. | Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol. 2013;62:3-26. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 119] [Cited by in F6Publishing: 128] [Article Influence: 12.8] [Reference Citation Analysis (1)] |
20. | Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, Zhou LY, Chen Y, Zeng ZR, Wang CW. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14:211-221. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 8.1] [Reference Citation Analysis (0)] |
21. | Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392-397. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 876] [Cited by in F6Publishing: 879] [Article Influence: 54.9] [Reference Citation Analysis (0)] |
22. | Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12 Suppl 2:32-38. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 144] [Cited by in F6Publishing: 159] [Article Influence: 9.4] [Reference Citation Analysis (0)] |
23. | Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: state of the art (review). Int J Oncol. 2013;42:5-18. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 135] [Cited by in F6Publishing: 152] [Article Influence: 12.7] [Reference Citation Analysis (0)] |
24. | Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881-1888. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 497] [Cited by in F6Publishing: 454] [Article Influence: 18.9] [Reference Citation Analysis (0)] |
25. | Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1015] [Cited by in F6Publishing: 994] [Article Influence: 49.7] [Reference Citation Analysis (0)] |
26. | Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-1540. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 239] [Cited by in F6Publishing: 243] [Article Influence: 12.8] [Reference Citation Analysis (0)] |
27. | Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037-1042. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 149] [Cited by in F6Publishing: 159] [Article Influence: 8.4] [Reference Citation Analysis (0)] |
28. | Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121-128. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 246] [Cited by in F6Publishing: 235] [Article Influence: 15.7] [Reference Citation Analysis (0)] |
29. | Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009;137:1641-1648.e1-2. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 194] [Cited by in F6Publishing: 198] [Article Influence: 13.2] [Reference Citation Analysis (0)] |
30. | Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488-492. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 314] [Cited by in F6Publishing: 330] [Article Influence: 27.5] [Reference Citation Analysis (1)] |
31. | Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54:735-738. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 4.7] [Reference Citation Analysis (0)] |
32. | Osborn JF, Cattaruzza MS, Ferri AM, De Angelis F, Renzi D, Marani A, Vaira D. How long will it take to reduce gastric cancer incidence by eradicating Helicobacter pylori infection? Cancer Prev Res (Phila). 2013;6:695-700. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
33. | Ihamäki T, Sipponen P, Varis K, Kekki M, Siurala M. Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results of long-term follow-up of three family samples. Scand J Gastroenterol Suppl. 1991;186:16-23. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
34. | Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:1110-1113. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 164] [Cited by in F6Publishing: 163] [Article Influence: 4.9] [Reference Citation Analysis (0)] |
35. | El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol. 2001;54:679-683. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
36. | Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449-1456. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 137] [Cited by in F6Publishing: 138] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
37. | Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, Xia Z, Guo H, Liu J, Chao W. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl). 2003;116:11-14. [PubMed] [Cited in This Article: ] |
38. | Watanabe H, Yamaguchi N, Kuwayama H, Sekine C, Uemura N, Kaise M, Nakamura T, Kubo M, Yoshida S, Haruma K. Improvement in gastric histology following Helicobacter pylori eradication therapy in Japanese peptic ulcer patients. J Int Med Res. 2003;31:362-369. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
39. | Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol. 1996;11:670-673. [PubMed] [Cited in This Article: ] |
40. | Annibale B, Aprile MR, D’ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther. 2000;14:625-634. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
41. | van der Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Keller JJ, Kruizinga SP, Dankert J, Tytgat GN. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113:25-30. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 147] [Cited by in F6Publishing: 138] [Article Influence: 5.1] [Reference Citation Analysis (0)] |
42. | Zerbib F, Lenk C, Sawan B, Cayla R, Broutet N, Carles B, de Mascarel A, Mégraud F, Lamouliatte H. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol. 2000;12:719-725. [PubMed] [Cited in This Article: ] |
43. | Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol. 2005;11:6518-6520. [PubMed] [Cited in This Article: ] |
44. | Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676-682. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 269] [Cited by in F6Publishing: 258] [Article Influence: 23.5] [Reference Citation Analysis (0)] |
45. | Kodama M, Murakami K, Okimoto T, Sato R, Uchida M, Abe T, Shiota S, Nakagawa Y, Mizukami K, Fujioka T. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012;47:394-403. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 7.7] [Reference Citation Analysis (0)] |
46. | de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009;104:1342-1345. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
47. | Ito M, Tanaka S, Takata S, Oka S, Imagawa S, Ueda H, Egi Y, Kitadai Y, Yasui W, Yoshihara M. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther. 2005;21:559-566. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 61] [Cited by in F6Publishing: 72] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
48. | Matsuo T, Ito M, Tatsugami M, Boda T, Takata S, Tanaka S, Chayama K. Gastric cancer development after Helicobacter pylori eradication therapy: a new form of gastric neoplasia. Digestion. 2012;85:61-67. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
49. | Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, Yoshio T, Nakamura T, Komori M, Kawai N. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013;62:1425-1432. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 158] [Cited by in F6Publishing: 195] [Article Influence: 17.7] [Reference Citation Analysis (0)] |
50. | Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy. 2005;37:990-993. [PubMed] [Cited in This Article: ] |
51. | Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1-12. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 299] [Cited by in F6Publishing: 284] [Article Influence: 10.9] [Reference Citation Analysis (0)] |
52. | Fujioka T, Yoshiiwa A, Okimoto T, Kodama M, Murakami K. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J Gastroenterol. 2007;42 Suppl 17:3-6. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
53. | Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639-642. [PubMed] [Cited in This Article: ] |
54. | Kato M, Asaka M. Recent development of gastric cancer prevention. Jpn J Clin Oncol. 2012;42:987-994. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
55. | Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75:39-46. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 134] [Cited by in F6Publishing: 150] [Article Influence: 12.5] [Reference Citation Analysis (0)] |
56. | Suheun B, Jung HY, Hyug LG, Don CK, June SH, Jin-Ho K, Do-hun K. Effect of eradication of Helicobacter pylori on recurrence after endoscopic mucosal resection of gastric adenoma and early gastric cancer. Gastroenterology. 2011;140:S-877. [DOI] [Cited in This Article: ] |
57. | Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, Lee JY, Lee JH, Ryu KW, Kim YW. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013;38:477-489. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
58. | O'Connor HJ, Dixon MF, Wyatt JI, Axon AT, Ward DC, Dewar EP, Johnston D. Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis. Lancet. 1986;2:1178-1181. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
59. | Dixon MF, Mapstone NP, Neville PM, Moayyedi P, Axon AT. Bile reflux gastritis and intestinal metaplasia at the cardia. Gut. 2002;51:351-355. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
60. | Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999;159:142-148. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
61. | Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, Bhandari P. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen. 2003;10:148-156. [PubMed] [Cited in This Article: ] |
62. | Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-154. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 208] [Cited by in F6Publishing: 224] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
63. | Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124:157-166. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis (0)] |
64. | Shin DW, Yun YH, Choi IJ, Koh E, Park SM. Cost-effectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer. Helicobacter. 2009;14:536-544. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
65. | Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis. 2009;200:1311-1317. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
66. | Van Ness M, Gregg J, Wang J, Chen M. Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine. J Gastrointest Oncol. 2012;3:243-251. [PubMed] [Cited in This Article: ] |
67. | Blaser M. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature. 2011;476:393-394. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 257] [Cited by in F6Publishing: 266] [Article Influence: 20.5] [Reference Citation Analysis (0)] |
68. | Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol. 2010;26:618-623. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
69. | Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 2011;22:375-387. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 108] [Cited by in F6Publishing: 127] [Article Influence: 9.1] [Reference Citation Analysis (0)] |
70. | Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010;105:1007-1013; quiz 1006, 1014. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis (0)] |